1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2022, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 10, 8, 2, 63, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 35 and 25 molecules, respectively.
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, 2022
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, 2022
- Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Acticule Life Sciences Ltd
- Acurx Pharmaceuticals Inc
- AEON Medix Inc
- AimMax Therapeutics Inc
- AlphaMab Co Ltd
- Amicrobe Inc
- Amprologix Ltd
- AnyGen Co Ltd
- Aphios Corp
- Aridis Pharmaceuticals Inc
- Arietis Corp
- Aurigene Discovery Technologies Ltd
- Basilea Pharmaceutica Ltd
- Bharat Biotech Ltd
- Biomendics LLC
- BioPlx Microbiomics Pvt Ltd
- Bioseka UAB
- Bioversys AG
- Botanix Pharmaceuticals Ltd
- Cantab Anti-infectives Ltd
- Cellics Therapeutics Inc
- Centivax Inc
- Chengdu Olymvax Biopharmaceuticals Inc
- Crestone Inc
- CrystalGenomics Inc
- CSA Biotechnologies LLC
- Curza Global LLC
- Daiichi Sankyo Co Ltd
- Debiopharm International SA
- DeNovaMed Inc
- Destiny Pharma Plc
- Eagle Pharmaceuticals Inc
- Enesi Pharma Ltd
- ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
- Exbaq LLC
- Global BioLife Inc Ltd
- Helperby Therapeutics Group Ltd
- Histogen Inc
- Hsiri Therapeutics LLC
- HyPharm GmbH
- ImmunArtes LLC
- Immupharma Plc
- Inimmune Corp
- Integrated BioTherapeutics Inc
- ioGenetics Inc
- Johnson & Johnson
- KBP Biosciences Co Ltd
- Lakewood-Amedex Inc
- Lead Discovery Center GmbH
- LegoChem Biosciences Inc
- Lysimmune BioScience
- Lyticon LLC
- Madam Therapeutics BV
- Matrisys Bioscience Inc
- Meiji Seika Pharma Co Ltd
- MGB Biopharma Ltd
- Microbiotix Inc
- MicuRx Pharmaceuticals Inc
- Naicons Srl
- Neupharma Srl
- Novabiotics Ltd
- Novalex Therapeutics Inc
- NovoBiotic Pharmaceuticals LLC
- Olgram SAS
- Opal Biosciences Ltd
- Oppilotech Ltd
- Oragenics Inc
- Oryn Therapeutics
- Oxford Drug Design Ltd
- Peptineo
- Pharma Holdings AS
- Phico Therapeutics Ltd
- Prokaryotics Inc
- Prommune Inc
- Q2 Pharma Ltd
- QureTech Bio AB
- Recce Pharmaceuticals Ltd
- Sano Chemicals Inc
- Scandion Oncology AS
- SciBac Inc
- Sentinella Pharmaceuticals Inc
- Shanghai Shangyao Xinya Pharmaceutical Co Ltd
- Shanghai Space Peptides Pharmaceutical Co Ltd
- Sinsa Labs Inc
- Skye Bioscience Inc
- Sorrento Therapeutics Inc
- Synspira Therapeutics Inc
- TaeJoon Pharmaceuticals Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
- TAXIS Pharmaceuticals Inc
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
- Theravance Biopharma Inc
- Trellis Bioscience Inc
- Venomyx Inc
- Viosera Therapeutics
- Vitas Pharma Research Pvt Ltd
- VLP Biotech Inc
- Wockhardt Ltd
- Yungjin Pharm Co Ltd
- Zhuhai Trinomab Biotechnology Co Ltd
- Zydus Lifesciences Ltd
